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INTRODUCTION 
Fenofibrate, chemically is 2-[4-(4-ch lorobenzoyl) 
phenoxy]-2-methyl p ropanoic acid 1-methyl ethyl ester 
1, 2
. 
It is the lipid regulating drug (BP 2009). Fenofibrate 
increases lipolysis and elimination of trig lyceride-rich  
particles from plasma by activating lipoprotein lipase and 
reducing production of apoprotein C-III (an inhibitor of 
lipoprotein lipase activity) 
3
. It is official in BP
 4
. Literature 
survey revealed that HPTLC
 5
 HPLC
 6
 and Stability 
Indicating UPLC 
7
 Method for simultaneous determination 
of Atorvastatin, Fenofibrate and their degradation products 
in tablets were reported. Also HPLC method has been 
reported for determination of Fenofib rate in human serum
 8-
10
 and urine 
11
.The present study describes the development 
and validation of a simple, specific, accurate and precise 
UVspectrophotometric method for determination of 
Fenofibrate in pharmaceutical dosage forms. 
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Figure 1: Chemical Structure of Fenofibrate  
MARERIAL AND METHOD  
Fenofibrate drug sample was supplied as gift sample by Sun 
Pharma Labs. Ltd., Jammu. Commercial tablets of 
Fenofibrate were procured from the market (FENOLIP-145 
mg from Cip la Pharma., STANLIP-160 mg from Ranbaxy  
Ltd., LOTZL-200 mg from Grandix lab) A ll other 
chemicals used were of analytical grade.  
Preliminary solubility studies of Fenofibrate
12-15
: 
solubilities of Fenofibrate were determined in 4 M sodium 
acetate and 1.25 M sodium cit rate solution, distilled water 
sufficient excess amount of drug was added to screw-
capped glass vials of 20 ml capacity, containing distilled  
water, and 4 M sodium acetate and 1.25 M sodium citrate 
solution. The vials were shaken mechanically for 12 hours 
at in orbital shaker (Khera Instrument Pvt. Ltd., India). The 
solutions were allowed to equilibrate for next 24 hours and 
then centrifuged for 5 min at 2000 rpm. The supernatant of 
each vial was filtered through Whatman filter paper # 41. 
Filtrates were diluted suitably and analyzed against 
corresponding solvent blanks. In this experiment mixed  
hydrotropy principle is applied in which to hydrotrops in 
different concentration were used for increasing the 
solubility of the drug for example 4 M sodium acetate and 
1.25 M sodium citrate. 
Analysis of Fenofibrate in tablets using 4 M sodium 
acetate and 1.25 M sodium citrate solution
13
: Twenty 
tablets of formulat ion-I (FENOLIP) were weighed and 
powdered. Powder equivalent to 145 mg Fenofibrate was 
transferred to a 50 ml volumetric flask containing 40 ml of 
4 M sodium acetate and 1.25 M sodium cit rate solution. The 
flask was shaken for about 5 min to solubilize the drug. 
Then volume was made up to the mark with distilled water. 
Solution was filtered through Whatman filter paper # 41. 
filtrate was divided in two parts, A and B. part A was kept 
at room temperature for 48 hours to check the effect on 
stability of drug in presence of sodium benzoate and also to 
note precipitation, if any, during this period.  Pa rt B filtrate 
was appropriately diluted with distilled water and 
absorbance was noted at 296 nm (λmax) against solvent 
blank and the drug content was calculated (Table-1). After 
48 hours, filtrate of part B was also appropriately diluted 
with distilled water and analyzed for drug content. There 
was no precipitation in the filtrate in 48 hours. Similar 
procedures were adopted in cases of formulation-II 
(STANLIP) and formulation-III (LOTZL). 
ABSTRACT 
A sensitive and rapid extractive spectrophotometer method has been developed for the assay of Fenofibrate in bulk 
drug and tablets. Fenofibrate shows maximum absorbance at 296 nm. Beer’s law was obeyed in the concentration range 
of in the range of 5-35µg/ml. Beers law was obeyed in this concentration range with correlation coefficient of 0.999. 
The concentrations of this drug were evaluated in laboratory mixture and marketed formulation. Accuracy was 
determined by recovery studies from tablet dosages forms and ranges from 99.33 -100.92 %. Precision of method was 
find out as repeatability, day to day and analyst to analyst variation and shows the values within acceptable limit (R.S.D 
≤ 2 percentage).   
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Figure 2 Scanning s pectra of Fenofibrate  
 
Figure 3 Standard Curve of Fenofibrate  
Table 1: Results of analysis of commercial tablets of Fenofibrate  
Tablet 
Formulation 
Label claim 
(mg) 
% Label claim 
Estimated* (Mean ± S .D.) 
% Coeff. of 
variation 
Standard 
error 
I (FENOLIP) 145 100.073± 0.7481 0.7476 0.3054 
II (STANLIP) 160 99.90 ± 0.1008 0.1009 0.0411 
III (LOTGL) 200 100.596 ±0.6114 0.6078 0.2734 
*Average of six determinations 
Recovery Studies
13-14
: 
Recovery studies are performed by adding extra bulk d rug 
nearly forty percent of formulations or more. For recovery 
studies, tablet powder of formulation I ((FENOLIP) 
equivalent to 145 mg drug was taken in a 25 ml volumetric 
flask. In this flask 70 mg of pure drug (corresponding 
spiked drug) was transferred and 20 ml of 4 M sodium 
acetate and 1.25 M sodium citrate solutions  were added 
and the flask was shaken for about 10 min. Then volume 
was made upto the mark with distilled water and filtered  
through Whatman filter paper # 41. The solution was 
diluted appropriately with distilled water and analyzed for 
drug content. Simila r procedures were adopted for 
formulat ion II (STANLIP) & formulat ion III (LOTZL). 
The results of analysis of recovery studies are presented in 
(Table 2)
Table 2: Recovery studies of commercial tablets of Fenofibrate  
Tablet 
Formulation 
Label claim 
(mg) 
Drug 
added 
(mg) 
 % Label claim 
Estimated*(Mean ± 
S .D.) 
% Coeff. of 
 Variation 
Standard 
error 
I (FENOLIP) 145 70 99.33 ± 1.762 0.1.774 0.719 
II (STANLIP) 160 80 100.61 ± 0.1.322 1.314 0.540 
III (LOTGL) 200 100 100.92 ±1.702 1.686 0.695 
*Average of six determinations 
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RESULT AND DISCUSSION  
The mean percent label claims estimated by proposed 
method for tablet formulations I, II and III  were 100.073, 
99.90 and 100.596, respectively  which are very close to 
100, indicating the accuracy of the method. This also 
indicates that there was no interference of sodium acetate, 
sodium citrate and the commonly used additives present in 
the tablet formulation in the estimation by the proposed 
method. Validation of the proposed method is further 
confirmed by the low values of standard deviation, percent 
coefficient of variation and standard error (Tab le 1). The 
mean percent recovery values ranged from 99.33 to 100.92 
and were very close to 100. Also the values of statistical 
parameters viz. standard deviation, percent coefficient of 
variation and standard error were significantly low (Table 
2). Thus, the proposed method of analysis was very well 
validated. 
Table 3: Stastiscal Data & Regression Equation for Fenofibrate  
Sr. No. Parameter Value 
1. λmax (nm) 296 
2. Beer’s range (μg/ml)  5-35 
3. Molar absorbtivity (l/mol/cm) 4.327 × 104 
4. Correlation coefficient (r2) 0.999 
5. Regression equation Y=0.059X +0.015 
6. Intercept (a) 0.015 
7. Slope (b) 0.059 
8.           Limit of detection (LOD μg/ml)  0.126 
9.          Limit of quantification(LOQ μg/ml)  0.406 
10. Linearity 1 – 18  
 
 
CONCLUS ION 
Thus, it may be concluded that the proposed method of 
analysis, using sodium acetate as the hydrotropic 
solubilizing agent is new, simple, cost-effective, 
environmentally friendly, safe, accurate and reproducible. 
Sodium acetate and the commonly used tablet excipients 
did not interfere in Spectrophotometric estimation at 296 
nm. Decided advantage is that organic solvents are 
precluded but not at the expense of accuracy. The 
proposed method is worth adopting in pharmacopoeia. By  
proper choice of hydrotropic agents, the use of organic 
solvents in analysis may be discouraged to a large extent. 
The proposed method shall prove equally effective to 
analyze Fenofibrate in the corresponding drug sample and 
may prove to be of great importance in pharmaceutical 
analysis. 
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